September 23rd 2020
Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.
John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.
Brian T. Hill, MD, PhD, discusses the impact of recent regulatory approvals in relapsed/refractory diffuse large B-cell lymphoma.
The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
The FDA has granted a priority review to a supplemental new drug application for crizotinib in the treatment of pediatric patients with ALK-positive relapsed/refractory systemic anaplastic large cell lymphoma.
September 22nd 2020
A biologics license application has been submitted to the FDA for loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Abhinav Deol, MD, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.
September 17th 2020
Catherine Lai, MD, MPH, discusses the significance of venetoclax in the acute myeloid leukemia treatment paradigm, the data from the VIALE-A trial, and remaining challenges faced in practice.
Oncologists who specialize in the treatment of hematologic malignancies participated in a virtual workshop to discuss the emerging treatment landscape in myelodysplastic syndromes.
